Thelansis’s "Fibrodysplasia Ossificans Progressiva (FOP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fibrodysplasia Ossificans Progressiva treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder caused by gain-of-function mutations in the ACVR1 gene. This encodes an overactive bone morphogenetic protein type I receptor (ALK2), driving the transformation of skeletal muscles, tendons, and ligaments into mature heterotopic bone. Congenital malformation of the great toes is present at birth, serving as a critical diagnostic clue before ossification begins. Progressive bone formation follows a cranial-to-caudal pattern, triggered by tissue trauma, surgical intervention, or inflammatory flare-ups, culminating in thoracic insufficiency and severe immobility. Diagnosis relies on clinical features and ACVR1 genetic testing, strictly avoiding tissue biopsy. The retinoic acid receptor gamma agonist palovarotene is an approved systemic standard to reduce new bone volume. In 2026, the advanced pipeline features two major FDA priority reviews: the anti-activin A antibody garetosmab, backed by Phase III OPTIMA data showing over a 90% reduction in new lesions, and the oral small molecule ALK2 inhibitor zilurgisertib, following pivotal Phase II PROGRESS trial data shared at ENDO 2026. Trauma avoidance remains core to care.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Fibrodysplasia Ossificans Progressiva (FOP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Fibrodysplasia Ossificans Progressiva (FOP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.